Thromboembolic complications are the main problem in stent-assisted coil embolization of unruptured intracranial aneurysms. The combination of aspirin and clopidogrel is generally used to decrease these complications, but some patients do not respond to clopidogrel and have a higher risk of stent thrombosis. In cardiology, clinical trials have shown that prasugrel reduced the incidence of ischaemic events in patients with acute coronary syndrome compared with clopidogrel but, according to several authors, prasugrel would produce an increased risk of cerebral haemorrhagic complications.
Objective
The purpose of this study was to determine whether prasugrel would be more effective than clopidogrel in reducing procedural events in patients with an unruptured aneurysm treated endovascularly with coils and stent.
Materials and methods
Two hundred consecutive patients with intracranial aneurysms were treated using coiling and stenting procedures. The first 100 patients were administered a dual antiplatelet of aspirin and clopidogrel, while the remaining 100 patients were administered a dual antiplatelet of aspirin and prasugrel. In each group data were collected on procedural and periprocedural haemorrhagic and ischaemic complications.
Results
Aneurysmal occlusion and haemorrhagic complications rates were identical in both groups. The number of thromboembolic events observed in the two groups of our study did not differ significantly, but the prasugrel group included more wide-neck aneurysms and more flow-diverted stents. Moreover, complications in the prasugrel group were more benign, explaining the significant difference in clinical outcomes between the two groups on Day 30.
Conclusions
Prasugrel reduces the clinical consequences of thromboembolic complications of endovascular treatment with stenting and coiling of unruptured intracranial aneurysms.
JahshanSAblaAANatarajanSK. Results of stent-assisted vs non-stent-assisted endovascular therapies in 489 cerebral aneurysms: Single-center experience. Neurosurgery2013; 72: 232–239.
2.
ShapiroMBecskeTSahleinD. Stent-supported aneurysm coiling: A literature survey of treatment and follow-up. Am J Neuroradiol2012; 33: 159–163.
3.
PiotinMBlancRSpelleL. Stent-assisted coiling of intracranial aneurysms: Clinical and angiographic results in 216 consecutive aneurysms. Stroke2010; 41: 110–115.
4.
AkpekSAratAMorsiH. Self-expandable stent-assisted coiling of wide-necked intracranial aneurysms: A single-center experience. AJNR Am J Neuroradiol2005; 26: 1223–1231.
5.
FargenKMHohBLWelchBG. Long-term results of enterprise stent-assisted coiling of cerebral aneurysms. Neurosurgery2012; 71: 239–244.
6.
FargenKMMoccoJNealD. A multicenter study of stent-assisted coiling of cerebral aneurysms with a Y configuration. Neurosurgery2013; 73: 466–472.
7.
MineBAljishiAD’HarcourJB. Stent-assisted coiling of unruptured intracranial aneurysms: Long-term follow-up in 164 patients with 183 aneurysms. J Neuroradiol2014; 41: 322–328.
8.
HettsSWTurkAEnglishJD. Matrix and Platinum Science Trial Investigators. Stent-assisted coiling versus coiling lone in unruptured intracranial aneurysms in the matrix and platinum science trial: Safety, efficacy, and mid-term outcomes. Am J Neuroradiol2014; 35: 698–705.
9.
MoccoJSnyderKVAlbuquerqueFC. Treatment of intracranial aneurysms with the Enterprise stent: A multicenter registry. J Neurosurg2009; 69: 908–913.
10.
FiorellaDAlbuquerqueFCDeshmukhVR. Usefulness of the Neuroform stent for the treatment of cerebral aneurysms: Results at initial (3–6-mo) follow-up. Neurosurgery2005; 56: 1191–1201.
11.
BiondiAJanardhanVKatzJM. Neuroform stent-assisted coil embolization of wide-neck intracranial aneurysms: Strategies in stent deployment and midterm follow-up. Neurosurgery2007; 61: 460–468.
12.
GalalABahrassaFDalfinoJC. Stent-assisted treatment of unruptured and ruptured intracranial aneurysms: Clinical and angiographic outcome. Br J Neurosurg2013; 27: 607–616.
13.
FiehlerJRiesT. Prevention and treatment of thromboembolism during endovascular aneurysm therapy. Klin Neuroradiol2009; 19: 73–81.
14.
ParkSHKimYBHuhSK. Effect of premedication method and drug resistance of antiplatelet agent on periprocedural thromboembolic events during coil embolization of an unruptured intracranial aneurysm. J Cerebrovasc Endovasc Neurosurg2012; 14: 148–156.
15.
AkbariSHReynoldsMRKadkhodayanY. Hemorrhagic complications after prasugrel (Effient) therapy for vascular neurointerventional procedures. J Neurointerv Surg2013; 5: 337–343.
16.
Leslie-mazwiTMChandraRVOhDC. Novel use of prasugrel for intracranial stent thrombosis. J NeuroIntervent Surg2011; 3: 358–360.
17.
RaymondJGuibertFWeillA. Long-term angiographic recurrences after selective endovascular treatment of aneurysms with detachable coils. Stroke2003; 34: 1398–1403.
18.
Yuan HogYWangYJDengZ. Stent-assisted coiling versus coiling in treatment of intracranial aneurysm: A systematic review and meta-analysis. PLoS One2014; 9: e82311.
19.
ConsoliAVignoliCRenieriL. Assisted coiling of saccular wide-necked unruptured intracranial aneurysms: Stent versus balloon. J Neurointerv Surg2016; 8: 52–57.
20.
NishidoHPiotinMBartoliniB. Analysis of complications and recurrences of aneurysm coiling with special emphasis on the stent-assisted technique. AJNR Am J Neuroradiol2014; 35: 339–344.
21.
VendrellJFCostalatVBrunelH. Stent-assisted coiling of complex middle cerebral aneurysms: Initial and midterm results. Am J Neuroradiol2011; 32: 259–263.
22.
HellerRSDandamudiVLanfranchiM. Effect of antiplatelet therapy on thromboembolism after flow diversion with the pipeline embolization device. J Neurosurg2013; 119: 1603–1610.
23.
McLaughlinNMcArthurDLMartinNA. Use of stent-assisted coil embolization for the treatment of wide-necked aneurysms: A systematic review. Surg Neurol Int2013; 4: 43–49.
24.
AngiolilloDJFernandez-OrtizABernardoE. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol2007; 49: 1505–1516.
25.
FerreiroJLAngiolilloDJ. Clopidogrel response variability: Current status and future directions. Thromb Haemost2009; 102: 7–14.
26.
NordeenJDPatelAVDarracottRM. Clopidogrel resistance by P2Y12 platelet function testing in patients undergoing neuroendovascular procedures: Incidence of ischemic and hemorrhagic complications. J Vasc Interv Neurol2013; 6: 26–34.
27.
GandhiCDBulsaraKRFifiJ. SNIS Standards and Guidelines Committee. Platelet function inhibitors and platelet function testing in neurointerventional procedures. J Neurointerv Surg2014; 6: 567–577.
28.
MaldonadoILSerisCMernesR. Clopidogrel-related platelet inhibition: Correlation with peri-operative adverse events in neurointerventional procedures. EJMINT2014. 1437000160 (epublication on 12 September 2014).
29.
BonelloLCamoin-JauLArquesS. Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: A multicenter randomized prospective study. J Am Coll Cardiol2008; 51: 1404–1411.
30.
OranICinarCBozkayaH. Tailoring platelet inhibition according to multiple electrode aggregometry decreases the rate of thrombotic complications after intracranial flow-diverting stent implantation. J Neurointerv Surg2015; 7: 357–362.
31.
ProtasiewiczMSzymkiewiczPKuliczkowskiW. Modern antiplatelet therapy – opportunities and risks. Adv Clin Exp Med2013; 22: 875–885.
32.
MehtaSRTanguayJFEikelboomJW. CURRENT-OASIS 7 trial investigators. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): A randomised factorial trial. Lancet2010; 376: 1233–1243.
33.
WiviottSDBraunwaldEMcCabeCH. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med2007; 357: 2001–2015.
34.
AngiolilloDJCapranzanoP. Pharmacology of emerging novel platelet inhibitors. Am Heart J2008; 156: S10–S15.
35.
RoffmanDS. Developments in oral antiplatelet agents for the treatment of acute coronary syndromes: Clopidogrel, prasugrel, and ticagrelor. J Pharm Pract2016; 29: 239–249.
36.
WangALellaLKBrenerSJ. Efficacy and safety of prasugrel compared with clopidogrel for patients with acute coronary syndrome undergoing percutaneous coronary intervention. Am J Ther2014; 17: 321–327.
37.
KaulUSethiAArambamP. Safety of prasugrel in Indian patients – multicentric registry of 1000 cases. Indian Heart J2014; 66: 598–601.
38.
Stetler wrChaudharyNThompsonBR. Prasugrel is effective and safe for neurointerventional procedures. J NeuroIntervent Surg2013; 5: 332–336.
39.
AkbariSHReynoldsMRKadkhodayanY. Hemorrhagic complications after prasugrel (Effient) therapy for vascular neurointerventional procedures. J NeuroIntervent Surg2013; 5: 337–343.
40.
JonesGMTwillaJDHoitDA. Prevention of stent thrombosis with reduced dose of prasugrel in two patients undergoing treatment of cerebral aneurysms with pipeline embolisation devices. J Neurointerv Surg2013; 26: e38.
41.
Delgado AlmandozJECrandallBMFeaseJL. Successful endovascular treatment of three fusiform cerebral aneurysms with the pipeline embolization device in a patient with dilating HIV vasculopathy. J Neurointerv Surg2014; 6: e12.
42.
HaEJChoWSKimJE. Prophylactic antiplatelet medication in endovascular treatment of intracranial aneurysms: Low-dose prasugrel versus clopidogrel. AJNR Am J Neuroradiol2016; 37: 1–6. .
43.
MontalescotGWiviottSDBraunwaldE. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): Double-blind, randomised controlled trial. Lancet2009; 373: 723–731.
44.
WiviottSDBraunwaldEAngiolilloDJ. TRITON-TIMI 38 Investigators. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel – Thrombolysis in Myocardial Infarction. Circulation2008; 118: 1626–1636.
45.
LhermusierTWaksmanR. Prasugrel hydrochloride for the treatment of acute coronary syndromes. Expert Opin Pharmacother2015; 16: 585–596.
46.
ZeymerUMochmannHCMarkB. Double-blind, randomized, prospective comparison of loading doses of 600 mg clopidogrel versus 60 mg prasugrel in patients with acute ST-segment elevation myocardial infarction scheduled for primary percutaneous intervention: The ETAMI Trial (Early Thienopyridine treatment to improve primary PCI in Patients with Acute Myocardial Infarction). JACC Cardiovasc Interv2015; 8: 147–154.
47.
ShankarJJTampieriDLancuD. SILK flow diverter for complex intracranial aneurysms: A Canadian registry. J Neurointerv Surg2016; 8: 273–278.
48.
BrinjikjiWMuradMHLanzinoG. Endovascular treatment of intracranial aneurysms with flow diverters: A meta-analysis. Stroke2013; 44: 442–447.
